Our Work
Latham Advises NVentures on Investment in CHARM Therapeutics
May 15, 2023
Firm represented NVIDIA’s venture capital arm on its investment in the 3D deep-learning biotechnology company.
CHARM Therapeutics (CHARM), a 3D deep-learning biotechnology company discovering and developing transformational medicines, has announced an investment from NVentures, NVIDIA’s venture investment arm. The investment represents a major milestone for CHARM, enabling the company to further deliver on its research and development activities in the area of novel medicines for oncology.
Latham & Watkins LLP represented NVentures in the transaction with a corporate team led by Bay Area partner Saad Khanani, with associates Omar Ammash and Beverly Cheung.